2-(pyridin-2YL)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulator
The invention relates to spiro derivative of formula (I), to the use of said derivative in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivative and processes for its preparation.
1. A compound of formula (I) which is 7-methyl-2-[4-[3-(trifluoromethoxy)phenyl]-2-pyridyl]-1,7-diazaspiro[4.4]nonan-6-one:
or a pharmaceutically acceptable salt thereof.
2. A compound as defined in claim 1 , wherein the compound of formula (I) is a compound of any one of formulae (Ia)-(Id):
or a pharmaceutically acceptable salt thereof.
3. A compound as defined in claim 2 , wherein the compound of formula (I) is a compound of formula (Ia):
or a pharmaceutically acceptable salt thereof.
4. A compound of formula (I) as defined in claim 1 , which is: (2R,5S)-7-Methyl-2-[4-[3-(trifluoromethoxy)phenyl]-2-pyridyl]-1,7-diazaspiro[4.4]nonan-6-one hydrochloride (E1).
5. A compound of formula (I) as defined in claim 1 , which is: (2R,5S)-7-Methyl-2-[4-[3-(trifluoromethoxy)phenyl]-2-pyridyl]-1,7-diazaspiro[4.4]nonan-6-one hemisulfate (E2).
6. A compound of formula (I) as defined in claim 1 , which is: (2S,5S)-7-Methyl-2-[4-[3-(trifluoromethoxy)phenyl]-2-pyridyl]-1,7-diazaspiro[4.4]nonan-6-one hydrochloride (E3).
7. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s).